A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus managed by diet therapy or one antidiabetic agent (sulfonylurea or alpha glucosidase inhibitor) will be candidates for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function.

Exclusion Criteria:

• Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.